The use of hexafluorodiethyl ether (indoklon) as an inhalant convulsant.

Although hexafluorodiethyl ether (CF3 CH,-O-CH2CF3) was originally synthesized for the purpose of determining whether it possessed anesthetic properties, it was found that the inhalation of its vapors produced convulsive seizures in many species of laboratory animals. This drug is now being investigated concerning its usefulness as a convulsant in the treatment of hospitalized psychiatric patients. To date a total of 434 treatments have been administered to a group of 40 patients. The only complication so far observed has been a compression fracture of a thoracic vertebra. Routine laboratory studies of blood, urine, and liver function as well as EKG studies have disclosed no abnormalities. The procedure for administering the drug is through the use of a Stephenson mask modified appropriately with one way valve to which the Indoklon vaporizer can be attached and the exhaled vapor absorbed by an activated charcoal exhalant(i). The dosage used varies according to the individual but remains within the range of 0.3 cc. to 1.5 cc. Treatments were given three times a week, and each patient received, on the average, 12 treatments. The time required to induce convulsions varies with each individual treatment, but has averaged about 30 seconds. The seizure begins with a few premonitary myoclonic jerks which are followed by the onset of a tonic phase without the marked “jack-knif-